Reported Q1 2026 revenue of $3.83 million, down from $4.24 million in Q1 2025. Net loss for the quarter was $1.47 million, compared to a $1.74 million loss in the prior-year period. Cash and restricted cash totaled $3.24 million as of March 31, 2026. Launched 'Strategic Ventures' segment to focus on technology and life sciences investments. Completed a $2.0 million public offering in January 2026. Approved a 1-for-40 reverse stock split to regain Nasdaq compliance.